Tarsus Pharmaceuticals, Inc.

Good morning, and welcome to TARCIS Year-End 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin.

Thank you. Before we begin, I encourage everyone to go to the Investor section of the TARCIS website to view the earnings release and related materials we will be discussing today. Joining me on the call this morning are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Modawala, our Chief Commercial Officer, Sesha Nirvanan, our Chief Operating Officer, and Jeff Farrell, our Chief Financial Officer and Chief Strategy Officer. I'd like to draw your attention to slide three, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. With that, I will turn the call over to Bobby.

Thank you, Dave. Good morning, everyone, and thank you for joining us. 2024 was a remarkable year for Tarsus by any metric. Not only did we exceed the lofty goals we'd set for ourselves with Xtembe, We also continue to advance a robust pipeline of other potential category-creating therapeutics, establishing a clear path forward to becoming the next leader in eye care. In 2024, our first full calendar year of Xtemby in the market, we generated more than $180 million in net product sales and delivered more than 163,000 bottles of Xtemby to patients. Even more exciting, we believe we are only beginning to scratch the surface of our ability to serve the millions of Americans with Demonex Blepharitis, or DB, that could immediately benefit from Xtemly. Much of our success is due to the tenacious effort of our sales force, which we expanded late last year from 100 to 150 sales representatives and leaders. With the expanded sales team activated in Q4, I am proud to say that more than 15,000 of our target eye care physicians, or ECPs, are now prescribing extembi. More importantly, and based on the positive patient outcomes our ECPs have seen within their own practices, the majority are moving more rapidly along the prescribing continuum from monthly to weekly to daily prescribing. Ease of access has also been a critical success factor. Thanks to the stellar work of our market access team, commercial and Medicare coverage of Xtemvi now extends to more than 90% of potential patient lives. Finally, we generated seminal data among DV patients with meibomian gland disease, or MGD, demonstrating that Xtemvi delivers both profound improvements in objective measures of disease and in patient outcomes like fluctuating vision. As you know, I like to get out in the field as often as I can, And during my most recent visits, I heard from ECPs again and again that Xtemvi continues to deliver great results for patients. There is no shortage of patients within their practices. The insurance coverage we've secured makes it easier and quicker to prescribe. Those who have seen the MGD data say it gives them yet another compelling reason to treat. And remember, we are just getting started there as well. On top of all this, we are already beginning to see the patient impact of the direct-to-consumer or DTC advertising campaign we launched late last year. And while the launch of XtemV continues to accelerate, we're just as excited about what's next for Tarsus. Earlier in this quarter, we introduced the next potentially transformative category in eye care, ocular rosacea. Much like DB, ocular rosacea is a chronic progressive disease caused by mice. We've learned just how pervasive this disease is from our ECPs who say they see it in their practice all the time. Leveraging the proven blueprint we've established with Xtembe and our ability to target the root cause of disease, we believe we can bring another transformational product to the millions of patients impacted by this disease. We plan to initiate a phase two trial of our ophthalmic gel formulation, TPO4, later this year. In addition to ocular rosacea, we are also advancing our Lyme disease prevention program. The FDA recently confirmed a clear regulatory path forward for this program, and we plan to initiate a phase two study in 2026. With our established ability to create new categories, an exceptional leadership team, and many opportunities ahead of us, I have no doubt 2025 will be even more impactful for Tarsus and for patients. With that, I will turn the call over to our Chief Commercial Officer, Aziz Motawala, for more details on our commercial progress.